tradingkey.logo

Intellia Therapeutics Inc <NTLA.OQ> expected to post a loss of $1.33 a share - Earnings Preview

ReutersFeb 25, 2025 1:39 PM
  • Intellia Therapeutics Inc NTLA.OQ NTLA.O is expected to show a rise in quarterly revenue when it reports results on February 27 for the period ending December 31 2024

  • The Cambridge Massachusetts-based company is expected to report a 545.1% decrease in revenue to $8.532 million from $-1.92 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Intellia Therapeutics Inc is for a loss of $1.33 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Intellia Therapeutics Inc is $46.00​, above​ its last closing price of $11.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-1.41

-1.38

-1.34

Beat

3.2

Jun. 30 2024

-1.25

-1.23

-1.52

Missed

-23.4

Mar. 31 2024

-1.39

-1.38

-1.12

Beat

18.8​

Dec. 31 2023

-1.45

-1.45

-1.46

Missed

-0.7

​​Sep. 30 2023

-1.49

-1.50

-1.38

Beat

7.9

Jun. 30 2023

-1.30

-1.32

-1.40

Missed

-6​

Mar. 31 2023

-1.41

-1.40

-1.17

Beat

16.4

Dec. 31 2022

-1.41

-1.39

-1.40

Missed

-0.5

This summary was machine generated February 25 at 13:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI